PERSISTENCE WHILE ON LABELED MAINTENANCE DOSE AMONG BIO-EXPERIENCED PATIENTS WITH CROHN'S DISEASE INITIATED ON USTEKINUMAB COMPARED TO ADALIMUMAB

被引：0
|
作者：
Zhdanava, Maryia
Ding, Zhijie
Manceur, Ameur
Kachroo, Sumesh
Holiday, Christopher
Zhao, Ruizhi
Pilon, Dominic
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S45 / S46
页数：2
相关论文
共 50 条
  • [41] Starting-dose trends over time in biologic-naive and biologic-experienced psoriasis patients initiated on ustekinumab or adalimumab
    Guerin, Annie
    Sundaram, Murali
    Gauthier, Genevieve
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB253 - AB253
  • [42] Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease
    Watanabe, Mamoru
    Hibi, Toshifumi
    Lomax, Kathleen G.
    Paulson, Susan K.
    Chao, Jingdong
    Alam, M. Shamsul
    Camez, Anne
    [J]. JOURNAL OF CROHNS & COLITIS, 2012, 6 (02): : 160 - 173
  • [43] Adalimumab maintenance therapy improves quality of life in patients with Crohn's disease
    [J]. Nature Reviews Gastroenterology & Hepatology, 2009, 6 (3) : 129 - 129
  • [44] Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease
    Loftus, Edward V., Jr.
    Johnson, Scott J.
    Yu, Andrew P.
    Wu, Eric Q.
    Chao, Jingdong
    Mulani, Parvez M.
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2009, 21 (11) : 1302 - 1309
  • [45] Induction and maintenance dose of adalimumab in 2 cohorts of Crohn's disease patients in the US: prescribed v. recommended
    Mackowialk, J.
    Sederman, R.
    [J]. INFLAMMATORY BOWEL DISEASES, 2008, 14 (01) : S19 - S19
  • [46] THE COST-EFFECTIVENESS OF USTEKINUMAB COMPARED TO INFLIXIMAB AND ADALIMUMAB IN ADULT PATIENTS WITH MODERATE-SEVERE CROHN'S DISEASE (TNF NAIVE POPULATION)
    Aliyev, E. R.
    Hay, J. W.
    Hwang, C.
    [J]. VALUE IN HEALTH, 2018, 21 : S84 - S84
  • [47] Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn’s Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States
    Camilo Obando
    Zhijie Ding
    Erik Muser
    Neel Vaidya
    Wenqin Qiang
    Xiaoxi Sun
    Huiqi Wang
    Rajesh Mallampati
    Lin Xie
    [J]. Advances in Therapy, 2020, 37 : 2127 - 2143
  • [48] Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn's Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States
    Obando, Camilo
    Ding, Zhijie
    Muser, Erik
    Vaidya, Neel
    Qiang, Wenqin
    Sun, Xiaoxi
    Wang, Huiqi
    Mallampati, Rajesh
    Xie, Lin
    [J]. ADVANCES IN THERAPY, 2020, 37 (05) : 2127 - 2143
  • [49] Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients
    Bultman, E.
    de Haar, C.
    van Liere-Baron, A.
    Verhoog, H.
    West, R. L.
    Kuipers, E. J.
    Zelinkova, Z.
    van der Woude, C. Janneke
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (03) : 335 - 341
  • [50] Adalimumab was more effective in the patients with bio-naive and early Crohn's disease
    Hisamatsu, T.
    Matsuoka, K.
    Naganuma, M.
    Miyoshi, J.
    Inoue, N.
    Yajima, T.
    Mizuno, S.
    Saigusa, K.
    Nakazato, Y.
    Mori, K.
    Takeshita, K.
    Nanki, K.
    Kiyohara, H.
    Iwao, Y.
    Ogata, H.
    Kanai, T.
    [J]. JOURNAL OF CROHNS & COLITIS, 2014, 8 : S305 - S305
12345